Ligand validation:7LLJ

30W: N-(6-formyl-4-oxo-3,4-dihydropteridin-2-yl)acetamide

30W is a Ligand Of Interest in 7LLJ designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
7LLJ_30W_E_301	26%	57%	0.318	0.961	0.59	1.02	1	1	2	0	100%	0.9412
7LLJ_30W_C_301	19%	57%	0.347	0.943	0.59	1.02	1	1	1	0	100%	0.9412
4PJH_30W_A_303	89%	27%	0.102	0.983	0.66	2.42	1	2	0	0	100%	0.9412
5D7I_30W_C_302	89%	64%	0.082	0.961	0.58	0.76	-	-	0	0	100%	0.9412
4PJ5_30W_C_600	86%	13%	0.104	0.974	2.03	2.12	5	7	0	0	100%	0.9412
4PJG_30W_C_301	86%	26%	0.109	0.978	0.68	2.41	1	3	1	0	100%	0.9412
4PJI_30W_C_301	81%	20%	0.127	0.98	0.89	2.66	1	2	0	0	100%	0.9412
4PJE_30W_A_306	80%	21%	0.13	0.98	0.6	2.84	-	3	0	0	100%	0.9412

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM133198.